InvestSMART

Cynata Therapeutics Limited (ASX: CYP) - Announcements

- Current share price for CYP : $0.011

ASX company news and announcements for Cynata Therapeutics Limited (CYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cynata Therapeutics Limited (CYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cynata Therapeutics Limited (CYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cynata Therapeutics Limited (CYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3 Appendix 3Y - Dr Kilian Kelly 19 Aug 2024 8:27AM $0.200 $0.011 fallen by 94.50%
$3 Notification of cessation of securities - CYP 19 Aug 2024 8:22AM $0.200 $0.011 fallen by 94.50%
$3 Cynata to Present at ISCT Meeting 9 Aug 2024 9:12AM $0.210 $0.011 fallen by 94.76%
$3 Study of Cymerus MSCs in Pulmonary Fibrosis Published 8 Aug 2024 9:49AM $0.210 $0.011 fallen by 94.76%
$3 Cleansing Notice 31 Jul 2024 12:11PM $0.250 $0.011 fallen by 95.60%
$3 Application for quotation of securities - CYP 31 Jul 2024 12:05PM $0.250 $0.011 fallen by 95.60%
$3 Quarterly Activity Report & Appendix 4C 30 Jul 2024 8:40AM $0.245 $0.011 fallen by 95.51%
$3 Application for quotation of securities - CYP 19 Jul 2024 3:08PM $0.260 $0.011 fallen by 95.77%
$3 Cynata Presents at Bioshares Summit 12 Jul 2024 9:20AM $0.250 $0.011 fallen by 95.60%
$3 Proposed issue of securities - CYP 1 Jul 2024 9:51AM $0.295 $0.011 fallen by 96.27%
$3 Cynata to Acquire IP from Tekcyte 1 Jul 2024 9:49AM $0.295 $0.011 fallen by 96.27%
$3 Sharewise Investor Presentation 27 Jun 2024 9:02AM $0.280 $0.011 fallen by 96.07%
$3 CYP Presents at Major International Cell Therapy Conference 29 May 2024 8:38AM $0.295 $0.011 fallen by 96.27%
$3 Further GvHD Clinical Data Published in Nature Medicine 22 May 2024 7:10PM $0.270 $0.011 fallen by 95.93%
$3 Appendix 3Y-Dr Geoffrey Brooke 17 May 2024 8:26AM $0.280 $0.011 fallen by 96.07%
$3 Notification of cessation of securities - CYP 17 May 2024 8:25AM $0.280 $0.011 fallen by 96.07%
$3 Investor Presentation 7 May 2024 11:35AM $0.235 $0.011 fallen by 95.32%
$3 Quarterly Activity Report & Appendix 4C 30 Apr 2024 8:54AM $0.210 $0.011 fallen by 94.76%
$3 Notification regarding unquoted securities - CYP 17 Apr 2024 1:36PM $0.200 $0.011 fallen by 94.50%
$3 DFU Clinical Trial Enrolment Complete 8 Apr 2024 8:58AM $0.195 $0.011 fallen by 94.36%
$3 EU Approval for Phase 2 CYP-001 Trial in GvHD 20 Mar 2024 8:55AM $0.170 $0.011 fallen by 93.53%
$3 Cynata Presenting at Advanced Therapies Congress 18 Mar 2024 8:52AM $0.170 $0.011 fallen by 93.53%
$3 First Patient Treated in Phase 2 GvHD Trial 5 Mar 2024 8:54AM $0.190 $0.011 fallen by 94.21%
$3 Cynata Appoints New Chief Business Officer 29 Feb 2024 9:19AM $0.210 $0.011 fallen by 94.76%
$3 Encouraging Initial Data from CYP-006TK DFU Trial 26 Feb 2024 9:01AM $0.200 $0.011 fallen by 94.50%

126 - 150 of 708 results

Page 6 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.